论文部分内容阅读
Aim:To investigate the effects of caffeic acid on early and delayed injuries afterfocal cerebral ischemia in rats,and the possible relation to 5-lipoxygenaseinhibition.Methods:Transient focal cerebral ischernia was induced by middlecerebral artery occlusion in Sprague-Dawley rats.Caffeic acid(10 and 50 mg/kg)was ip injected for 5 d after ischemia.The brain injuries were observed,and thelevels of cysteinyl leukotrienes and leukotriene B_4 in the brain tissue weremeasured.Results:Caffeic acid(50 mg/kg)ameliorated neurological dysfunctionand neuron loss,and decreased infarct volume 24 h after ischemia;it attenuatedbrain atrophy,infarct volume,and particularly astrocyte proliferation 14 d afterischemia.In addition,it reduced the production of leukotrienes(5-lipoxygenasemetabolites)in the ischemic hemispheres 3 h and 7 d after ischemia.Conclusion:Caffeic acid has protective effect on both early and delayed injuries after focalcerebral ischemia in rats;and this effect may partly relate to 5-lipoxygenaseinhibition.
Aim: To investigate the effects of caffeic acid on early and delayed injuries afterfocal cerebral ischemia in rats, and the possible relation to 5-lipoxygenase inhibition. Methods: Transient focal cerebral ischernia was induced by middle cerebral artery occlusion in Sprague-Dawley rats. Caffeic acid ( 10 and 50 mg / kg) was ip injected for 5 days after the brain injuries were observed, and the levels of cysteinyl leukotrienes and leukotriene B_4 in the brain tissue were measured. Results: Caffeic acid (50 mg / kg) ameliorated neurological dysfunction and neuron loss, and decreased infarct volume 24 h after ischemia; it attenuatedbrain atrophy, infarct volume, and particularly astrocyte proliferation 14d afterischemia.In addition, it reduced the production of leukotrienes (5-lipoxygenasemetabolites) in the ischemic hemispheres 3 h and 7 d after ischemia.Conclusion: Caffeic acid has protective effect on both early and delayed injuries after focal cerebral ischemia in rats; and this effect may partly relate to 5- lipoxygenase inhibitor.